Sara Willa Ernst is a reporter with The Cancer Letter. She joined the publication in 2025.
Before joining The Cancer Letter, Sara reported on health in Texas both as a freelance journalist based in Austin and the health reporter at the NPR station in Houston, where she produced two investigative podcasts "Hot Stops" and "Below the Waterlines." The latter won her two regional Murrow awards in 2023.
Her bylines have appeared in publications such as NPR, The Texas Standard, WHYY's The Pulse, WBUR's Here and Now, Austin Free Press and the Austin Chronicle.
She graduated from Vanderbilt University with a bachelor's degree in Communications Studies in 2018.
Latest Stories
NCI
NCI has released the names of the members of the newly formed ad hoc Working Group on Extramural Research Concepts and Programs. The group will perform the peer review functions of the now-defunct Board of Scientific Advisors.
As NCI and NIH funding is being deliberated in Congress, this year’s 2025 AACR Cancer Progress Report had an unequivocal message: With 20 new anticancer therapeutics, new uses for eight previously approved anticancer therapeutics, two new early detection tools, and several AI-powered diagnostics approved over the span of just one year, cancer research funding yields a good return on investment.
The National Cancer Advisory Board approved five reissue concepts at a meeting Sept. 4.
Cancer Policy
To fight drug shortages that have dogged all of medicine—including oncology—for decades, the Trump administration is returning to a policy it first enacted during the president’s first term.
Cancer Policy
A federal judge ruled that the Trump Administration’s move to cut research funding to Harvard University was illegal—restoring more than $2 billion and all future grants to the institution.
Cancer Policy
FDA is shortening its timeline for publicizing Complete Response Letters, pledging to make them available to the public “promptly” after sponsors receive notice.
Podcast
Phil and Penny Knight made a record-setting $2 billion gift to OHSU Knight Cancer Institute.
Free
Earlier this year, amid efforts by the Trump administration to reduce the federal workforce, Lakshmi Grama decided to take early retirement from NCI.
Those anxiously anticipating the release of the U.S. News & World Report‘s evaluation of cancer hospitals will find one intriguing change.
Conversation with The Cancer Letter
The first large cancer screening/early detection initiative to be launched in 2025—the NCI-funded Vanguard study of multi-cancer detection tests—has started accruing patients through nine sites across the U.S.
Conversation with The Cancer Letter
On July 4, President Donald Trump signed into law “The One Big Beautiful Bill Act,” which is expected to deal a massive blow to Medicaid coverage and leave millions without insurance by instituting a work requirement for beneficiaries.
Regulatory News
The FDA Oncologic Drugs Advisory Committee July 17 recommended against approval of a Blenrep-based regimen for the treatment of relapsed or refractory multiple myeloma, citing unacceptable rates of ocular toxicity and overall poor tolerability of the drug.
Cancer Policy
The U.S. Department of Health and Human Services is searching for examples of employees, grant recipients, and contractors harmed by DEI efforts of the federal government in the last five years, as part of the Trump administration’s mission to end initiatives set up to diversify the workforce and bolster opportunities forhistorically disadvantaged groups.